Oral Proteins and Peptides Market Key Players Analysis - AstraZeneca, Biocon Chiasma, Novo Nordisk A/S, Allergan.

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Oral Proteins and Peptides Market"-, By Type of Target Disease Indication (Acromegaly, Celiac Disease, Chronic Idiopathic Constipation, Enteric Hyperoxaluria, Inflammatory Bowel Disease, and Type II Diabetes), Type of Molecule (Protein and Peptide), Type of Biological Target (GC-C, Insulin Receptor, Oxalate and others), Type of Mechanism of Action (Receptor Stimulation, Substrate Degradation and Others), and Global Forecasts, 2024-2031 And Segment Revenue and Forecast To 2031."

The Oral Proteins and Peptides Market is estimated to reach over USD 28.17 billion by 2031, exhibiting a CAGR of 20.3% during the forecast period.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2868

Proteins and peptides, the fundamental elements of life, hold tremendous potential for treating various diseases. Over the past 30 years, especially in the last decade, the development of therapeutic proteins has advanced rapidly, leading to a significant increase in the number of protein-based medications available on the market. However, these molecules have very low bioavailability when taken orally due to their delicate tertiary structure and complex spatial conformation, which are easily degraded in the harsh environment of the gastrointestinal tract. To increase the availability of oral peptides, improvements in their formulation are expected to enhance oral absorption. Some promising therapeutic peptides, such as Octreotide using Peptelligence technology and oral semaglutide based on Eligen technology, have already entered the clinical phase.

Advances in peptide formulation technologies have significantly enhanced the bioavailability of oral peptide therapies. Innovations such as nanoparticle encapsulation, structural modifications of peptides, and the use of permeation enhancers protect peptides from degradation in the gastrointestinal tract, making oral administration more feasible. Oral peptides provide a non-invasive alternative to injections, improving patient compliance and adherence to treatment regimens, which is particularly crucial for managing chronic conditions that require long-term care. Furthermore, regulatory support for innovative therapies, including Fast Track Designation and Breakthrough Therapy Designation from agencies like the FDA, enables companies to expedite the approval process for oral peptides, facilitating their faster market entry. Collaborations between pharmaceutical companies, biotechnology firms, and research institutions also play a vital role in accelerating the discovery and development of novel oral protein and peptide therapies by fostering knowledge sharing and resource allocation. Additionally, increased investment in R&D by pharmaceutical and biotechnology companies can lead to the identification of new peptides with therapeutic potential, further driving market innovation and expansion.

List of Prominent Players in the Oral Proteins and Peptides Market:
• AstraZeneca
• Biocon Chiasma
• Novo Nordisk A/S
• Allergan
• Oramed Pharmaceuticals
• Proxima Concepts
• Synergy Pharmaceuticals
• Tarsa Therapeutics
• Sanofi
• F. Hoffmann-La Roche Ltd
• Novo Nordisk A/S
• Abbvie Inc.
• Pfizer Inc.
• Bausch Health Companies Inc.
• Chiesi Farmaceutici S.P.A.
• Acadia Pharmaceuticals Inc.
• Aurinia Pharmaceuticals Inc.
• Merck & Co., Inc.
• Johnson & Johnson Services, Inc.
• Swk Holdings
• R-Pharm Jsc
• Entera Bio Ltd.
• Proxima Concepts
• Astrazeneca Plc
• Regor Therapeutics Group
• Terns Pharmaceuticals, Inc.
• Structure Therapeutics
• Viking Therapeutics
• Protagonist Therapeutics Inc.
• Rani Therapeutics
• Carmot Therapeutics, Inc.
• Zealand Pharma
• Sciwind Biosciences Co., Ltd.
• Jiangsu Hengrui Pharmaceuticals Co., Ltd

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-02

Market Dynamics:
Drivers:
Innovations such as nanoparticle carriers, enteric coatings, and enzyme inhibitors have improved the stability and bioavailability of proteins and peptides, making oral delivery more feasible. The rising incidence of chronic conditions such as diabetes, cancer, and hormonal disorders increases the demand for effective and patient-friendly treatment options. Regulatory agencies like the FDA have been approving novel oral protein and peptide therapies, fostering confidence in the development of these treatments and encouraging further investment. As a non-invasive substitute for conventional injections, oral formulations like those being developed for insulin and other peptide-based therapies have the potential to enhance patient compliance and quality of life. These developments put oral proteins and peptides at the forefront of managing chronic diseases in the future by meeting the increasing need for more patient-friendly therapies. The aging global population, more susceptible to chronic diseases, is creating a greater demand for advanced, easy-to-administer treatments, further fueling market growth.

Challenges:
Developing stable and effective oral formulations of proteins and peptides is technically challenging. The need for advanced formulation technologies, such as encapsulation or modification strategies, increases development costs and timelines. One of the primary challenges for oral proteins and peptides is their low bioavailability due to degradation by gastrointestinal enzymes and the acidic environment of the stomach.

Regional Trends:
North America has the largest market share during the forecast period due to the region has strong focus on research and development, with numerous biotechnology and pharmaceutical companies investing heavily in innovative peptide therapies. Favorable regulatory policies, such as Fast Track and Breakthrough Therapy Designations, facilitate quicker approval processes for new oral peptide therapies. However, The Asia-Pacific region is projected to witness the highest growth rate due to increasing healthcare expenditures, a rising patient population, and greater awareness of peptide-based therapies. Efforts to streamline regulatory processes in emerging markets are facilitating faster approvals for innovative therapies. Countries like China and India are seeing significant investments in biotechnology, leading to increased research activities and the development of oral peptide therapies.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2868

Recent Developments:
• In June 2023, Pfizer Inc. declared its intention to proceed with the clinical development of a single oral late-stage glucagon-like peptide-1 receptor agonist (GLP-1-RA) candidate for the possible treatment of people with Type 2 diabetes mellitus (T2DM) and obesity. Subject to the outcomes of the ongoing Phase 2 trial, the company will proceed with the clinical development of lotiglipron (PF-07081532) and continue to advance the clinical program for danuglipron (PF-06882961). The business is working on a once-daily modified release version of danuglipron and anticipates having preparations for the late-stage program finalized by the end of 2023.
• In August 2023, Entera Bio, presented abstracts at the annual conference of the American Society for Bone and Mineral Research (ASBMR) on its First-in-Class, Once Daily Oral hPTH(1-34) Peptide Tablets (EB613) for the treatment of postmenopausal women at high risk of fracture.

Segmentation of Oral Proteins and Peptides Market.
Global Oral Proteins and Peptides Market- Type of Target Disease Indication
• Acromegaly
• Celiac Disease
• Chronic Idiopathic Constipation
• Enteric Hyperoxaluria
• Inflammatory Bowel Disease
• Type II Diabetes
Global Oral Proteins and Peptides Market - Type of Molecule
• Protein
• Peptide
Global Oral Proteins and Peptides Market - Type of Biological Target
• GC-C
• Insulin Receptor
• Oxalate
• Others
Global Oral Proteins and Peptides Market - Type of Mechanism of Action
• Receptor Stimulation
• Substrate Degradation
• Others
Global Oral Proteins and Peptides Market - By Region
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• Southeast Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of the Middle East and Africa

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.